Breast (Feb 2021)
Impact of body mass index on overall survival in patients with metastatic breast cancer
- Khalil Saleh,
- Matthieu Carton,
- Véronique Dieras,
- Pierre-Etienne Heudel,
- Etienne Brain,
- Véronique D’Hondt,
- Audrey Mailliez,
- Anne Patsouris,
- Marie-Ange Mouret-Reynier,
- Anthony Goncalves,
- Jean Marc Ferrero,
- Thierry Petit,
- George Emile,
- Lionel Uwer,
- Marc Debled,
- Florence Dalenc,
- Christelle Jouannaud,
- Sylvain Ladoire,
- Marianne Leheurteur,
- Paul Cottu,
- Lucie Veron,
- Alexia Savignoni,
- Coralie Courtinard,
- Mathieu Robain,
- Suzette Delaloge,
- Elise Deluche
Affiliations
- Khalil Saleh
- Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
- Matthieu Carton
- Department of Biostatistics, Institut Curie, 26 Rue D’Ulm, 75005, Paris & Saint-Cloud, France
- Véronique Dieras
- Medical Oncology Department, Centre Eugéne Marquis, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France
- Pierre-Etienne Heudel
- Department of Medical Oncology, Centre Léon Bérard, 28 Prom. Léa et Napoléon Bullukian, 69008, Lyon, France
- Etienne Brain
- Department of Medical Oncology, Institut Curie, Saint-Cloud, France
- Véronique D’Hondt
- Department of Medical Oncology, Institut Du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, INSERM U1194, University of Montpellier, France
- Audrey Mailliez
- Medical Oncology Department, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France
- Anne Patsouris
- Department of Medical Oncology, Institut de Cancérologie de L’Ouest Nantes & Angers, 15 Rue André Boquel, 49055, Angers, France
- Marie-Ange Mouret-Reynier
- Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont Ferrand, France
- Anthony Goncalves
- Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France
- Jean Marc Ferrero
- Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France
- Thierry Petit
- Department of Medical Oncology, Centre Paul Strauss, 3 Rue de La Porte de L’Hôpital, 67000, Strasbourg, France
- George Emile
- Department of Medical Oncology, Centre François Baclesse, 3 Avenue Du Général Harris, 14000, Caen, France
- Lionel Uwer
- Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, 6 Avenue de Bourgogne, 54519, Vandœuvre-lès-Nancy, France
- Marc Debled
- Department of Medical Oncology, Institut Bergonie, 229 Cours de L’Argonne, F-33000, Bordeaux, France
- Florence Dalenc
- Department of Medical Oncology, Institut Claudius Regaud – IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France
- Christelle Jouannaud
- Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue Du Général Koenig, 51100, Reims, France
- Sylvain Ladoire
- Department of Medical Oncology, Centre Georges François Leclerc, 1 Rue Professeur Marion, 21079, Dijon, France
- Marianne Leheurteur
- Department of Medical Oncology, Centre Henri Becquerel, Rue D’Amiens, 76000, Rouen, France
- Paul Cottu
- Department of Medical Oncology, Institut Curie, 26 Rue D’Ulm, 75005, Paris & Saint-Cloud, France
- Lucie Veron
- Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France
- Alexia Savignoni
- Department of Biostatistics, Institut Curie, 26 Rue D’Ulm, 75005, Paris & Saint-Cloud, France
- Coralie Courtinard
- Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654, Paris, France
- Mathieu Robain
- Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654, Paris, France
- Suzette Delaloge
- Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France; Corresponding author. Department of Cancer Medicine, Gustave Roussy 114 rue Edouard Vaillant, Villejuif, 94805, France
- Elise Deluche
- Department of Cancer Medicine, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France; Department of Medical Oncology, CHU de Limoges, 2 Avenue Martin Luther King, Limoges, France
- Journal volume & issue
-
Vol. 55
pp. 16 – 24
Abstract
Background: High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC). Methods: The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers. Results: Of 22 463 patients in ESME-MBC, 12 999 women had BMI data available at MBC diagnosis. Median BMI was 24.9 kg/m2 (range 12.1–66.5); 20% of women were obese and 5% underweight. Obesity was associated with more de novo MBC, while underweight patients had more aggressive cancer features. Median overall survival (OS) of the BMI cohort was 47.4 months (95% CI [46.2–48.5]) (median follow-up: 48.6 months). Underweight was independently associated with a worse OS (median OS 33 months; HR 1.14, 95%CI, 1.02–1.27) and first line progression-free survival (HR, 1.11; 95%CI, 1.01; 1.22), while overweight or obesity had no effect. Conclusion: Overweight and obesity are not associated with poorer outcomes in women with metastatic disease, while underweight appears as an independent adverse prognostic factor.
